Login to Your Account



Other News To Note


Wednesday, April 4, 2012
• Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said the FDA extended the PDUFA date for Lymphoseek (99m-Tc-Tilmanocept) by 90 days, to Sept. 10, after the company provided updated chemistry, manufacturing and control information requested by the agency within the 90-day period prior to the original PDUFA date. Lymphoseek is a radioactive tracing agent for lymphatic mapping and lymphoscintigraphy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription